They Just Don't Get...
Health Care: Drugs
EntreMed Inc. (ENMD: NASDAQ)
$2.03 0.07 | 3.57%
06/04/12 - 03:59 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 1.08M | 4.89M | 6.31M | 16.74M |
| Receivables | 1.93M | 2.75M | 3.29M | 3.92M |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 3.21M | 7.93M | 9.87M | 28.59M |
| Property, Plant & Equipment, Gross | 417.40K | 6.30M | 6.32M | 6.31M |
| Accumulated Depreciation & Depletion | 392.78K | 6.19M | 6.14M | 6.05M |
| Property, Plant & Equipment, Net | 24.62K | 104.73K | 171.50K | 263.72K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 4.18K | 4.58K | 21.49K | 67.46K |
| Total Non-Current Assets | 28.80K | 109.31K | 192.99K | 331.17K |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 3.24M | 8.04M | 10.07M | 28.92M |
| Accounts Payable | 453.33K | 1.35M | 1.97M | 11.20M |
| Short Term Debt | 0.00 | 757.47K | 8.56M | 20.76K |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 704.09K | 2.70M | 11.27M | 13.81M |
| Long Term Debt | 0.00 | 0.00 | 723.81K | 9.19M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 0.00 | 0.00 | 723.81K | 9.19M |
| Total Liabilities | 704.09K | 2.70M | 11.99M | 23.00M |
| Preferred Stock Equity | 3.35M | 3.35M | 3.35M | 3.35M |
| Common Stock Equity | -818.26K | 1.98M | -5.28M | 2.57M |
| Common Par | 122.38K | 115.18K | 886.72K | 884.89K |
| Additional Paid In Capital | 385.88M | 384.13M | 368.00M | 367.69M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -378.79M | -374.23M | -366.13M | -357.91M |
| Treasury Stock | -8.03M | -8.03M | -8.03M | -8.03M |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | -58.39K |
| Total Capitalization | 2.53M | 5.33M | -1.20M | 15.11M |
| Total Equity | 2.53M | 5.33M | -1.93M | 5.92M |
| Total Liabilities & Stock Equity | 3.24M | 8.04M | 10.07M | 28.92M |
| Total Common Shares Outstanding | 12.24M | 11.52M | 8.06M | 7.98M |
| Preferred Shares | 3.35M | 3.35M | 3.35M | 3.35M |
| Treasury Shares | 79.54K | 79.54K | 79.54K | 79.54K |
| Basic Weighted Shares Outstanding | 11.78M | 9.68M | 7.98M | 7.86M |
| Diluted Weighted Shares Outstanding | 11.78M | 9.68M | 7.98M | 7.86M |
| Number of Employees | 7 | 12 | 13 | 21 |
| Number of Part-Time Employees | 1 | 2 | 1 | 0 |
Portfolios with ENMD
- Portfolio NameUser Type
- Contributor6 Drug Stocks Unworthy of B...
- UserBeaver
- Contributor10 Stocks Under $5 Outperfo...
- ContributorStocks Under $5 at Risk of ...
- UserDorkingLad Portfolio 1
- Usersmallbiz
- Usersteves #1
- UserThe Investment Psychologist...
- Userdrweik Portfolio 1
- UserJake's Portfolio 1
Latest ENMD Headlines from TheStreet
- 6 Drug Stocks Unworthy of Biotech Bull Market 02.07.12 | 12:02 pm
- 5 Stocks Under $10 Poised for Big Upside 02.03.12 | 02:02 pm
- 10 Stocks Under $5 Outperforming in 2012 01.31.12 | 05:01 am
- Stocks Under $5 at Risk of Bankruptcy 06.08.11 | 06:06 am
- Biotech Sector Weekly Rewind 11.20.10 | 08:11 am
- Stock Offerings: Two Harbors 04.19.10 | 10:04 am
- Sprint Nextel, Palm: Early Volume Plays 04.19.10 | 07:04 am
- ThermoGenesis, Power-One: Early Volume Plays 02.05.10 | 07:02 am
- Netlist, EntreMed: Midday Volume Plays 12.14.09 | 02:12 pm
- ExpressJet, Entremed: Midday Volume Plays 11.16.09 | 02:11 pm
Press Releases for ENMD
- EntreMed Appoints Interim CEO - PR Newswire 04.03.12 | 07:04 am
- EntreMed Initiates Plans For China Office - PR Newswire 03.05.12 | 02:03 pm
- EntreMed Completes Strategic Financing - PR Newswire 02.06.12 | 07:02 am
- Biotech Leaders Wei-Wu He, Ph.D And Tak W. Mak, Ph.D Join EntreMed's Board Of Directors - PR Newswire 02.06.12 | 07:02 am
- EntreMed's ENMD-2076 Demonstrates Promising Activity In A Phase 2 Study In Platinum-Resistant Ovarian Cancer Patients - PR Newswire 10.03.11 | 07:10 am
- EntreMed Enters Into $7.5 Million Equity Facility And Initiates $1.1 Million Drawdown - PR Newswire 06.28.11 | 05:06 pm
- Selected Value Therapeutics Exercises Right To Develop And Commercialize Enmd-2076 In China - PR Newswire 06.07.11 | 11:06 am
- EntreMed's ENMD-2076 Demonstrates Clinical Activity In Recurrent, Platinum-Resistant Ovarian Cancer Patients - PR Newswire 06.03.11 | 03:06 pm
- EntreMed Reports Fourth Quarter And Year-End 2009 Financial Results - PR Newswire 03.29.10 | 04:03 pm
Partner Headlines for ENMD
- China Biotech In Review: GSK Explores All Paths To Increase China Presence - Seeking Alpha 03.11.12 | 07:03 am
- China Biotech Week in Review: Shanghai Pharma Plans $1.2 Billion IPO - Seeking Alpha 09.12.10 | 09:09 am
- Big Pharma Looks to Biotech for Innovation - Seeking Alpha 09.12.10 | 08:09 am
- EntreMed Widens Loss in 2Q, Clinical Trials for Ovarian Cancer Progress - Fox Business 08.16.10 | 12:08 pm
